Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04088786 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial HIPEC With Nal-irinotecan
A Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04088786 is a Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 18 participants.
The verdict
NCT04088786, a Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as possible, and heated intraperitoneal chemotherapy (HIPEC) procedures.
Interventions
- DRUG nanoliposomal irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-10-22 |
| Est. Completion | 2022-04-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04088786
The ClinicalTrials.gov registry entry for NCT04088786 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which nanoliposomal irinotecan is the first listed.
NCT04088786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04088786 about?
NCT04088786 is a clinical study titled "Phase I Trial HIPEC With Nal-irinotecan". The purpose of this study is to assess the effectiveness and safety of intraperitoneal administration of heated nanoliposomal Irinotecan in cytoreductive surgery (CRS), which is surgery designed to remove as much of the cancer as possible, and heated intraperitoneal chemotherapy (HIPEC) procedures.
What is the current status of trial NCT04088786?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-10-22. Estimated completion is 2022-04-14.
What interventions are being tested in trial NCT04088786?
The interventions under investigation include: nanoliposomal irinotecan (DRUG).
Who is sponsoring clinical trial NCT04088786?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.